유방암 환자의 화학요법제 저항성 예측을 위한 혈청 바이오마커
    1.
    发明公开
    유방암 환자의 화학요법제 저항성 예측을 위한 혈청 바이오마커 有权
    乳腺癌耐药性预测的血清生物标记蛋白

    公开(公告)号:KR1020130086898A

    公开(公告)日:2013-08-05

    申请号:KR1020120008011

    申请日:2012-01-26

    Abstract: PURPOSE: A biomarker for diagnosing resistance to a chemotherapeutic agent in a patient with breast cancer is provided to enable an individual patient to select a treatment direction and to enhance survival rate of the patient without recurrence. CONSTITUTION: A composition for diagnosing resistance to a chemotherapeutic agent in a patient with breast cancer contains antibodies which specifically bind to proteins selected among a group consisting of alpha-2-HS-glycoprotein, apolipoprotein B, complement component 3, complement component 9, ceruloplasmin, and orosomucoid 1. A kit for diagnosing resistance to a chemotherapeutic agent contains the antibodies. A microarray for diagnosing resistance to a chemotherapeutic agent contains the antibodies.

    Abstract translation: 目的:提供一种用于诊断患有乳腺癌患者化疗药物的耐药性的生物标志物,以使个体患者能够选择治疗方向并提高患者的存活率而无复发。 构成:用于诊断患有乳腺癌患者的化学治疗剂的抗性的组合物含有特异性结合选自α-2-HS-糖蛋白,载脂蛋白B,补体成分3,补体成分9,血浆铜蓝蛋白 和血清霉糖苷酶1.用于诊断对化学治疗剂的抗性的试剂盒含有抗体。 用于诊断抗化学治疗剂的微阵列包含抗体。

    유방암 환자의 항암제 내성 진단용 바이오 마커 및 키트
    3.
    发明授权
    유방암 환자의 항암제 내성 진단용 바이오 마커 및 키트 有权
    生物标志物用于诊断乳腺癌患者和试剂盒的抗癌药物抗性

    公开(公告)号:KR101096928B1

    公开(公告)日:2011-12-22

    申请号:KR1020090024700

    申请日:2009-03-24

    Abstract: 본발명은유방암환자에대해선별적인수술전항암화학요법을시행하기위한유방암환자의항암제내성진단용바이오마커및 키트에관한것으로서, 본발명은유방암환자의항암제내성진단용바이오마커, 유방암환자의항암제내성진단에필요한정보를제공하기위한, 상기바이오마커단백질의인산화정도측정방법및 유방암환자의항암제내성진단용키트를제공한다. 본발명은유방암환자의항암제내성을조기에예측할수 있게하여유방암환자에대한선택적, 개별적항암제사용이가능하게하며, 이를통해유방암환자삶의질 향상은물론항암제관련의료비용의합리적사용을유도할수 있을것으로기대된다.

    유방암 환자의 항암제 내성 진단용 바이오 마커 및 키트
    4.
    发明公开
    유방암 환자의 항암제 내성 진단용 바이오 마커 및 키트 有权
    用于诊断乳腺癌患者和试剂盒抗癌药物耐药性的生物标志物

    公开(公告)号:KR1020100106637A

    公开(公告)日:2010-10-04

    申请号:KR1020090024700

    申请日:2009-03-24

    Abstract: PURPOSE: A biomarker and kit for diagnosing anticancer drug resistance of a patient with breast cancer is provided to early predict the anticancer drug resistance. CONSTITUTION: A biomarker for diagnosing anticancer drug resistance of a patient with breast cancer has an amino acid sequence of sequence number 1. The anticancer drug is an anthracycline anticancer drug. A kit for diagnosing anticancer drug resistance of a patient with breast cancer comprises the biomarker protein or antibody which specifically binds to an immunogenic fragment thereof and phosphorylated biomarker or antibody which specifically binds to an immunogenic fragment. The kit additionally contains a secondary antibody conjugate, chromogenic solution, washing solution, and enzymes reaction stopping liquid. The secondary antibody conjugate is HRP(horseradish peroxidase), alkaline phosphatase, colloid gold, fluorescence or dye.

    Abstract translation: 目的:提供用于诊断乳腺癌患者抗癌药物耐药性的生物标志物和试剂盒,以早期预测抗癌药物耐药性。 构成:用于诊断乳腺癌患者抗癌药物耐药性的生物标志物具有序列号1的氨基酸序列。抗癌药物是蒽环类抗癌药物。 用于诊断患有乳腺癌患者的抗癌药物抗性的试剂盒包含特异性结合其免疫原性片段的生物标记蛋白或抗体,以及与免疫原性片段特异性结合的磷酸化生物标志物或抗体。 该试剂盒另外含有二抗结合物,显色溶液,洗涤液和酶反应停止液。 第二抗体缀合物是HRP(辣根过氧化物酶),碱性磷酸酶,胶体金,荧光或染料。

Patent Agency Ranking